In addition, patients with advanced HR-positive, HER2-negative breast cancer whose disease progressed after nonsteroidal aromatase inhibitors were used were enrolled in a multicenter, randomised, double-blind, placebo-controlled phase III research (E2112). Here, CYP19A1 is linked to breast carcinoma.